VNDA
Vanda Pharmaceuticals Inc. Healthcare - Biotechnology Investor Relations →
Vanda Pharmaceuticals Inc. (VNDA) closed at $7.12 as of 2026-03-20, trading 17.4% above its 200-week moving average of $6.07. The stock is currently moving closer to the line, down from 44.9% last week. The 14-week RSI sits at 54, indicating neutral momentum.
Trading volume is running at 1.9x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.47 ratio) is neutral — neither side is clearly dominating.
Over the past 992 weeks of data, VNDA has crossed below its 200-week moving average 18 times. On average, these episodes lasted 31 weeks. The average one-year return after crossing below was -17.5%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $421 million, VNDA is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -50.9%. The stock trades at 1.3x book value.
Share count has increased 4.1% over three years, indicating dilution.
Over the past 19.1 years, a hypothetical investment of $100 in VNDA would have grown to $29, compared to $651 for the S&P 500. VNDA has returned -6.2% annualized vs 10.3% for the index, underperforming the broader market over this period.
Free cash flow has been declining at a -100% compound annual rate. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: VNDA vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After VNDA Crosses Below the Line?
Across 17 historical episodes, buying VNDA when it crossed below its 200-week moving average produced an average return of -22.2% after 12 months (median -25.0%), compared to +4.9% for the S&P 500 over the same periods. 18% of those episodes were profitable after one year. After 24 months, the average return was -11.9% vs +19.6% for the index.
Each line shows $100 invested at the moment VNDA crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
VNDA has crossed below its 200-week MA 18 times with an average 1-year return of +-17.5% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jul 2007 | Oct 2007 | 10 | 15.9% | -93.9% | -56.2% |
| Oct 2007 | May 2009 | 81 | 95.2% | -94.7% | -54.7% |
| Oct 2009 | Nov 2009 | 1 | 0.1% | -28.3% | -30.2% |
| Jan 2010 | Feb 2010 | 1 | 2.3% | -20.0% | -28.9% |
| Apr 2010 | Dec 2010 | 34 | 38.0% | -4.2% | -15.2% |
| Jan 2011 | Apr 2011 | 13 | 11.7% | -36.0% | -11.6% |
| May 2011 | Jun 2011 | 7 | 5.1% | -41.0% | -2.6% |
| Aug 2011 | May 2013 | 94 | 56.5% | -40.7% | +5.5% |
| Nov 2013 | Nov 2013 | 1 | 6.0% | +88.9% | +14.1% |
| Nov 2015 | Dec 2015 | 2 | 6.4% | +74.1% | -20.5% |
| Jan 2016 | May 2016 | 20 | 19.2% | +87.0% | -13.3% |
| May 2019 | Nov 2019 | 27 | 20.0% | -25.0% | -53.4% |
| Dec 2019 | Feb 2021 | 58 | 48.7% | -18.2% | -55.7% |
| Mar 2021 | Apr 2021 | 2 | 3.0% | -25.9% | -54.0% |
| Aug 2021 | Aug 2021 | 3 | 2.0% | -34.1% | -55.5% |
| Nov 2021 | Dec 2021 | 2 | 3.2% | -32.7% | -56.1% |
| Dec 2021 | Dec 2025 | 207 | 70.6% | -52.9% | -54.6% |
| Feb 2026 | Feb 2026 | 2 | 5.6% | N/A | +16.9% |
| Average | 31 | — | +-17.5% | — |
Frequently Asked Questions
Is VNDA below its 200-week moving average?
No. Vanda Pharmaceuticals Inc. (VNDA) is currently 17.4% above its 200-week moving average of $6.07. It would need to fall to $6.07 to cross below the line.
What is VNDA's 200-week moving average price?
Vanda Pharmaceuticals Inc.'s 200-week moving average is $6.07 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when VNDA drops below its 200-week moving average?
VNDA has crossed below its 200-week moving average 18 times in our data. The average one-year return after these crossings was -17.5%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 31 weeks on average.
Is VNDA a good value right now?
Here's what our data says about VNDA as of 2026-03-20: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 54. Free cash flow is currently negative. Return on equity is -50.9%. Price-to-book is 1.3x. This is not a buy or sell recommendation — always do your own research.
How does VNDA compare to the S&P 500?
Over the past 19.1 years, $100 invested in VNDA would have grown to $29, compared to $651 for the S&P 500. That's -6.2% annualized vs 10.3% for the index. VNDA has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20